Cargando…

Virological failure among people living with HIV receiving second-line antiretroviral therapy in Pune, India

BACKGROUND: The number of people receiving second-line antiretroviral therapy (ART) has increased as global access to ART has expanded. Data on the burden and factors associated with second-line ART virologic failure (VF) from India remain limited. METHODS: We conducted cross-sectional viral load (V...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvi, Sonali, Raichur, Priyanka, Kadam, Dileep, Sangle, Shashikala, Gupte, Nikhil, Nevrekar, Neetal, Patil, Sandesh, Chavan, Amol, Nimkar, Smita, Marbaniang, Ivan, Mave, Vidya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758821/
https://www.ncbi.nlm.nih.gov/pubmed/36528762
http://dx.doi.org/10.1186/s12879-022-07894-2
_version_ 1784852122362183680
author Salvi, Sonali
Raichur, Priyanka
Kadam, Dileep
Sangle, Shashikala
Gupte, Nikhil
Nevrekar, Neetal
Patil, Sandesh
Chavan, Amol
Nimkar, Smita
Marbaniang, Ivan
Mave, Vidya
author_facet Salvi, Sonali
Raichur, Priyanka
Kadam, Dileep
Sangle, Shashikala
Gupte, Nikhil
Nevrekar, Neetal
Patil, Sandesh
Chavan, Amol
Nimkar, Smita
Marbaniang, Ivan
Mave, Vidya
author_sort Salvi, Sonali
collection PubMed
description BACKGROUND: The number of people receiving second-line antiretroviral therapy (ART) has increased as global access to ART has expanded. Data on the burden and factors associated with second-line ART virologic failure (VF) from India remain limited. METHODS: We conducted cross-sectional viral load (VL) testing among adults (≥ 18 years) who were registered at a publicly funded ART center in western India between 2014 and 2015 and had received second-line ART for at least 6 months. Sociodemographic and clinical characteristics were abstracted from routinely collected programmatic data. Logistic regression evaluated factors associated with VF (defined as VL > 1000 copies/mL). RESULTS: Among 400 participants, median age was 40 years (IQR 34–44), 71% (285/400) were male, and 15% (59/400) had VF. Relative to participants without VF, those with VF had lower median CD4 counts (230 vs 406 cells/mm(3), p < 0.0001), lower weight at first-line failure (49 vs 52 kg, p = 0.003), were more likely to have an opportunistic infection (17% vs 3%, p < 0.0001) and less likely to have optimal ART adherence (71% vs 87%, p = 0.005). In multivariable analysis, VF was associated with opportunistic infection (aOR, 4.84; 95% CI, 1.77–13.24), lower CD4 count (aOR 4.15; 95% CI, 1.98–8.71) and lower weight at first-line failure (aOR, 2.67; 95% CI, 1.33–5.34). CONCLUSIONS: We found second-line VF in about a sixth of participants in our setting, which was associated with nearly fivefold increased odds in the context of opportunistic infection. Weight could be a useful clinical indicator for second-line VF. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07894-2.
format Online
Article
Text
id pubmed-9758821
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97588212022-12-18 Virological failure among people living with HIV receiving second-line antiretroviral therapy in Pune, India Salvi, Sonali Raichur, Priyanka Kadam, Dileep Sangle, Shashikala Gupte, Nikhil Nevrekar, Neetal Patil, Sandesh Chavan, Amol Nimkar, Smita Marbaniang, Ivan Mave, Vidya BMC Infect Dis Research BACKGROUND: The number of people receiving second-line antiretroviral therapy (ART) has increased as global access to ART has expanded. Data on the burden and factors associated with second-line ART virologic failure (VF) from India remain limited. METHODS: We conducted cross-sectional viral load (VL) testing among adults (≥ 18 years) who were registered at a publicly funded ART center in western India between 2014 and 2015 and had received second-line ART for at least 6 months. Sociodemographic and clinical characteristics were abstracted from routinely collected programmatic data. Logistic regression evaluated factors associated with VF (defined as VL > 1000 copies/mL). RESULTS: Among 400 participants, median age was 40 years (IQR 34–44), 71% (285/400) were male, and 15% (59/400) had VF. Relative to participants without VF, those with VF had lower median CD4 counts (230 vs 406 cells/mm(3), p < 0.0001), lower weight at first-line failure (49 vs 52 kg, p = 0.003), were more likely to have an opportunistic infection (17% vs 3%, p < 0.0001) and less likely to have optimal ART adherence (71% vs 87%, p = 0.005). In multivariable analysis, VF was associated with opportunistic infection (aOR, 4.84; 95% CI, 1.77–13.24), lower CD4 count (aOR 4.15; 95% CI, 1.98–8.71) and lower weight at first-line failure (aOR, 2.67; 95% CI, 1.33–5.34). CONCLUSIONS: We found second-line VF in about a sixth of participants in our setting, which was associated with nearly fivefold increased odds in the context of opportunistic infection. Weight could be a useful clinical indicator for second-line VF. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07894-2. BioMed Central 2022-12-17 /pmc/articles/PMC9758821/ /pubmed/36528762 http://dx.doi.org/10.1186/s12879-022-07894-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Salvi, Sonali
Raichur, Priyanka
Kadam, Dileep
Sangle, Shashikala
Gupte, Nikhil
Nevrekar, Neetal
Patil, Sandesh
Chavan, Amol
Nimkar, Smita
Marbaniang, Ivan
Mave, Vidya
Virological failure among people living with HIV receiving second-line antiretroviral therapy in Pune, India
title Virological failure among people living with HIV receiving second-line antiretroviral therapy in Pune, India
title_full Virological failure among people living with HIV receiving second-line antiretroviral therapy in Pune, India
title_fullStr Virological failure among people living with HIV receiving second-line antiretroviral therapy in Pune, India
title_full_unstemmed Virological failure among people living with HIV receiving second-line antiretroviral therapy in Pune, India
title_short Virological failure among people living with HIV receiving second-line antiretroviral therapy in Pune, India
title_sort virological failure among people living with hiv receiving second-line antiretroviral therapy in pune, india
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758821/
https://www.ncbi.nlm.nih.gov/pubmed/36528762
http://dx.doi.org/10.1186/s12879-022-07894-2
work_keys_str_mv AT salvisonali virologicalfailureamongpeoplelivingwithhivreceivingsecondlineantiretroviraltherapyinpuneindia
AT raichurpriyanka virologicalfailureamongpeoplelivingwithhivreceivingsecondlineantiretroviraltherapyinpuneindia
AT kadamdileep virologicalfailureamongpeoplelivingwithhivreceivingsecondlineantiretroviraltherapyinpuneindia
AT sangleshashikala virologicalfailureamongpeoplelivingwithhivreceivingsecondlineantiretroviraltherapyinpuneindia
AT guptenikhil virologicalfailureamongpeoplelivingwithhivreceivingsecondlineantiretroviraltherapyinpuneindia
AT nevrekarneetal virologicalfailureamongpeoplelivingwithhivreceivingsecondlineantiretroviraltherapyinpuneindia
AT patilsandesh virologicalfailureamongpeoplelivingwithhivreceivingsecondlineantiretroviraltherapyinpuneindia
AT chavanamol virologicalfailureamongpeoplelivingwithhivreceivingsecondlineantiretroviraltherapyinpuneindia
AT nimkarsmita virologicalfailureamongpeoplelivingwithhivreceivingsecondlineantiretroviraltherapyinpuneindia
AT marbaniangivan virologicalfailureamongpeoplelivingwithhivreceivingsecondlineantiretroviraltherapyinpuneindia
AT mavevidya virologicalfailureamongpeoplelivingwithhivreceivingsecondlineantiretroviraltherapyinpuneindia